# UK Structural Heart Devices Market

> UK Structural Heart Devices Market Research Report: Size, Share, Trend Analysis By Types (Heart Valve Devices, Annuloplasty Rings, Occluders, Delivery Systems), By Indication (Valvular Heart Disease, Cardiomyopathy) andBy Procedure (Replacement Procedures, Repair Procedures) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.63%
- **2024:** $ 28.88 Million
- **2025:** $ 30.79 Million
- **2035:** $ 58.5 Million
- **Key Players:** Edwards Lifesciences (US), Medtronic (US), Abbott Laboratories (US), Boston Scientific (US), LivaNova (GB), Terumo Corporation (JP), Cardinal Health (US), AtriCure (US)

**Report ID:** MRFR/HC/55134-HCR · **Pages:** 200 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** February 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/uk-structural-heart-devices-market-56900

---

## Market Summary

## **UK Structural Heart Devices Market Overview****:**

As per MRFR analysis, the UK Structural Heart Devices Market Size was estimated at 43.74 (USD Million) in 2024.The UK Structural Heart Devices Market Industry is expected to grow from 47.43(USD Million) in 2025 to 104 (USD Million) by 2035. The UK Structural Heart Devices Market CAGR (growth rate) is expected to be around 7.398% during the forecast period (2025 - 2035).

### **Key UK Structural Heart Devices Market Trends Highlighted**

The UK Structural Heart Devices Market is currently shaped by several notable trends. An increasing prevalence of cardiovascular diseases, particularly among the aging population in the UK, is driving the demand for structural heart devices. The National Health Service (NHS) emphasizes the need for innovative solutions to manage conditions like aortic stenosis and mitral valve disorders, which are common in older adults. 

Different hospitals and healthcare systems are actively incorporating advanced techniques and technologies, reflecting a trend toward less invasive procedures, such as transcatheter interventions, over traditional surgical methods.Key market drivers include the urgent need for effective treatment options that enhance patient outcomes and reduce recovery times. With the NHS focusing on improving healthcare delivery and outcomes, there is a growing emphasis on investing in and adopting advanced medical technologies that facilitate early diagnosis and treatment of heart conditions. 

Additionally, the increasing number of clinical trials in the UK, supported by governmental health initiatives, continues to foster innovation in device development and applications. There are significant opportunities to be explored within the UK market. The rise of telemedicine and remote monitoring solutions, spurred by the COVID-19 pandemic, creates a new avenue for the integration of structural heart devices and patient management systems.Furthermore, collaborations between medical device manufacturers and healthcare providers can enhance research and development capabilities, leading to tailored solutions that meet specific patient needs in the UK. 

Recent trends indicate a shift toward personalized medicine, where treatments and devices are being customized based on patient profiles. With continued advancements, the UK Structural Heart Devices Market is poised for further growth as healthcare providers look to improve cardiovascular care and outcomes for their patients.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **UK Structural Heart Devices Market Drivers**

### **Increasing Prevalence of Heart Diseases in the UK**

The UK has seen a significant rise in cardiovascular diseases, becoming a major health concern. According to the National Health Service (NHS) reports, approximately 7.6 million people in the UK are living with heart and circulatory diseases. This number reflects a growing population suffering from conditions such as heart valve disorders, which directly drives the UK [Structural Heart Devices Market](../../../reports/structural-heart-devices-market-6385) Industry. As the prevalence of these diseases continues to rise, the demand for surgical interventions and innovative devices will increase significantly.

Research from leading organizations such as the British Heart Foundation (BHF) indicates a forecasted increase of 22% in the prevalence of heart disease among individuals aged 65 and over within the next decade, further accentuating the critical need for structural heart devices. The healthcare system's focus on early diagnosis and treatment options will drive innovations and market penetration in this sector, leading to increased expenditure and investment in structural heart technologies.

### **Technological Advancements in Medical Devices**

Emerging technologies such as minimally invasive surgical techniques and innovative device designs are revolutionizing the UK Structural Heart Devices Market Industry. The integration of digital health solutions and advancements in imaging techniques have paved the way for better patient outcomes and increased procedural accuracy. According to the UK Government's Department of Health and Social Care, investments in medical technology are expected to grow as they translate into more efficient and effective healthcare delivery.The development of transcatheter heart valves is being led by companies like Edwards Lifesciences and Medtronic.

These valves are expected to greatly improve patient recovery periods while minimizing complications. This elegant approach is predicted to shift the requirements of the industry, attracting healthcare employees and hospitals to take up the newly developed technologies.

### **Government Initiatives and Healthcare Policies**

The UK government has been proactive in promoting awareness and regulatory frameworks around cardiovascular diseases, positively influencing the UK Structural Heart Devices Market Industry. The introduction of strategies such as the NHS Long Term Plan emphasizes the importance of cardiovascular health and encourages investments in diagnostic and therapeutic medical devices.

This initiative has led to increased funding for Research and Development (R&D) in this sector, ultimately supporting the growth of innovative structural heart devices.Furthermore, regulations and frameworks that ease the approval process for new medical technologies, as demonstrated by the Medicines and Healthcare Products Regulatory Agency (MHRA), provide a conducive environment for market growth. The UK's commitment to reducing the burden of heart disease is expected to propel the market forward, aligning with the rising demand for advanced treatment options.

## **UK Structural Heart Devices Market Segment Insights****:**

### **Structural Heart Devices Market Type Insights**

The UK Structural Heart Devices Market, particularly focusing on the Type segment, encompasses a variety of crucial medical devices essential for treating heart conditions. This market primarily comprises Heart Valve Devices, which play a pivotal role in managing valvular heart diseases, providing patients with improved life quality and longevity through various surgical interventions. Annuloplasty Rings are integral in heart valve repair procedures and are favored for their capacity to enhance outcomes by restoring proper valve function. 

Additionally, Occluders serve an essential function by preventing undesirable blood flow in cases of congenital heart defects, showcasing their significance in pediatric and adult populations.The Delivery Systems aspect of this market greatly impacts the efficacy of these devices, ensuring precise placement and enhancing overall procedural success rates. The evolving landscape in the UK is marked by rising healthcare expenditure and a growing population of elderly individuals, which collectively act as catalysts for market growth. Innovations in technology, alongside improved surgical techniques, contribute to the increasing adoption of these devices. 

Challenges such as regulatory approvals and the high cost of advanced devices exist; however, opportunities abound due to the ongoing demand for minimally invasive procedures and the anticipated increase in heart-related ailments.Such dynamics within the UK Structural Heart Devices Market segmentation underscore both the complexity and importance of each type of device, showcasing their integral roles in modern cardiac care. The synthesis of market data reveals trends reflecting the rising incidence of cardiac disorders, thus necessitating the continual advancement of these innovative solutions to meet patient needs effectively.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Structural Heart Devices Market Indication Insights**

The Indication segment of the UK Structural Heart Devices Market showcases a focus on specific cardiovascular conditions such as Valvular Heart Disease and Cardiomyopathy. Valvular Heart Disease is a significant concern, as it affects a considerable number of individuals in the UK, often leading to serious complications if not treated appropriately. 

The increasing prevalence of this condition underscores the demand for advanced intervention technologies, thereby driving growth in this segment. Moreover, Cardiomyopathy, characterized by the deterioration of the heart muscle, presents unique challenges in treatment options, driving innovation and expansion within the Structural Heart Devices Market.This segment is crucial as it encompasses various therapeutic devices aimed at improving patient outcomes and quality of life. 

The potential for technological advancements and the rising awareness of these conditions among healthcare professionals and patients further enhance the importance of the Indication segment in the overall UK Structural Heart Devices Market landscape. Given the challenges associated with both conditions, various stakeholders, including healthcare providers and device manufacturers, continue to explore novel solutions to address these prevalent heart diseases effectively.

### **Structural Heart Devices Market Procedure Insights**

The UK Structural Heart Devices Market showcases significant growth under the Procedure segment, driven by an increasing prevalence of structural heart diseases and advancements in medical technology. In this market, Replacement Procedures and Repair Procedures play pivotal roles in addressing various cardiac conditions. Replacement Procedures are crucial for patients suffering from severe valve diseases, offering innovative solutions that enhance patient outcomes. 

Similarly, Repair Procedures have gained traction due to their less invasive nature, catering to a growing demand for safer treatment options with shorter recovery times.The emphasis on improving clinical outcomes and minimizing patient discomfort fuels growth in these areas. Moreover, an aging population in the UK, coupled with rising healthcare expenditures, creates a favorable environment for the expansion of these procedures. 

As the demand for effective management of structural heart conditions increases, the importance of these procedures in the UK Structural Heart Devices Market continues to rise, reflecting the industry's commitment to enhancing cardiac care. Ultimately, the dynamics of these procedures contribute significantly to the overall market growth, as they align with emerging trends and advancements within the UK healthcare landscape.

## **UK Structural Heart Devices Market Key Players and Competitive Insights****:**

The UK Structural Heart Devices Market is a dynamic and evolving sector characterized by rapid advancements in technology and a growing demand for innovative treatment solutions for cardiac conditions. The market involves a range of devices, including transcatheter heart valves, left atrial appendage closure devices, and other implantable products aimed at addressing various structural heart diseases. 

The competitive landscape in this market is shaped by several key players who are continuously investing in research and development to enhance their offerings and gain a larger market share. As the UK healthcare system seeks to improve patient outcomes, reduce hospital stays, and streamline costs, companies within this market are focusing on providing effective and minimally invasive solutions that can be delivered safely and efficiently in a clinical setting.Medtronic stands out as a prominent player in the UK Structural Heart Devices Market, leveraging its extensive experience and innovative prowess to deliver high-quality cardiac solutions. 

The company is well-known for its cutting-edge devices that cater specifically to the needs of cardiologists and patients dealing with structural heart issues. Medtronic's strengths in the UK market are underscored by its strong brand recognition, a robust portfolio of products including transcatheter heart valves, and a commitment to investing in advanced technologies. Additionally, Medtronic benefits from strong relationships with healthcare providers and favorable reimbursement policies in the UK, which enable wider access to its products. 

The company's ongoing focus on clinical trials and collaborations with leading hospitals further bolsters its position in the competitive landscape, allowing it to stay ahead of emerging trends and address specific patient needs effectively.AtriCure is another key player in the UK Structural Heart Devices Market, specializing in surgical and catheter-based solutions for treating atrial fibrillation and other structural heart disorders. The company's key products include ablation devices and closure devices aimed at managing atrial fibrillation and reducing stroke risk associated with left atrial appendage. 

AtriCure's strengths in the UK market lie in its innovative product offerings and a strong emphasis on clinical evidence supporting the efficacy and safety of its devices. The company has made significant strides in establishing its market presence, which is aided by strategic partnerships and collaborations with healthcare institutions across the UK. AtriCure has also looked to expand its reach through various mergers and acquisitions, enhancing its capabilities and strengthening its position within the structural heart landscape.

This strategic approach, combined with a growing portfolio of high-quality products, allows AtriCure to effectively compete in the evolving UK market and cater to the needs of patients and healthcare providers alike.

### **Key Companies in the UK Structural Heart Devices Market Include:**

- [Medtronic](https://www.medtronic.com/in-en/healthcare-professionals/education-training/medical-education/therapies/structural-heart.html)
- AtriCure
- Neovasc
- Abbott Laboratories
- Corvia Medical
- MicroPort Scientific
- Boston Scientific
- Philips
- Cardinal Health
- LivaNova
- SentreHEART
- Edwards Lifesciences
- Terumo Corporation
- GSI Group
- Johnson & Johnson

## **UK Structural Heart Devices Market Industry Developments**

_The UK Structural Heart Devices Market has witnessed significant developments in recent months, particularly with advancements in minimally invasive procedures and the adoption of innovative technologies. Companies like Medtronic and Abbott Laboratories continue to lead in product innovations, focusing on devices such as transcatheter aortic valves and left atrial appendage closure devices. In April 2023, Boston Scientific announced the successful completion of its acquisition of a portfolio of innovative structural heart offerings from a smaller firm, enhancing its market presence in the UK. Additionally, Edwards Lifesciences has expanded its range of heart valve replacement solutions, bolstering its competitive position. _

_The growing incidence of heart diseases, supported by statistics from the UK NHS indicating a constant rise in cardiovascular conditions among aging populations, has led to surges in demand for structural heart devices. These developments contribute to a market projected to grow significantly, with analysts citing that the UK market's value will increase notably by 2025. Recent efforts by Terumo Corporation and MicroPort Scientific to collaborate with healthcare providers for streamlining__treatment protocols reflect a shift towards improved patient outcomes in structural heart conditions, further underlining the dynamic nature of this sector._

## **UK Structural Heart Devices Market Segmentation Insights**

### **Structural Heart Devices Market Type****Outlook**

- Heart Valve Devices
- Annuloplasty Rings
- Occluders
- Delivery Systems

### **Structural Heart Devices Market Indication****Outlook**

- Valvular Heart Disease
- Cardiomyopathy

### **Structural Heart Devices Market Procedure****Outlook**

- Replacement Procedures
- Repair Procedures

## Market Drivers

### Growing Awareness and Education

There is a notable increase in awareness and education regarding cardiovascular health among both healthcare professionals and the general public in the UK. Campaigns aimed at educating individuals about the risks associated with heart diseases and the benefits of early intervention are gaining traction. This heightened awareness is likely to drive demand for structural heart devices, as patients become more informed about their treatment options. Additionally, healthcare professionals are increasingly trained in the latest technologies and procedures related to structural heart devices, which may lead to more referrals and procedures being performed. As a result, the structural heart-devices market is poised for growth as both patients and providers recognize the importance of timely and effective treatment.

### Increased Healthcare Expenditure

The structural heart-devices market is significantly influenced by the rising healthcare expenditure in the UK. Recent reports indicate that the UK government has committed to increasing the NHS budget, which is projected to reach £200 billion by 2024. This financial commitment allows for the adoption of advanced medical technologies, including structural heart devices, which are essential for treating complex cardiovascular conditions. As healthcare providers allocate more resources towards innovative treatments, the market for structural heart devices is expected to expand. Furthermore, increased funding for research and development in this sector may lead to the introduction of new and improved devices, thereby enhancing the overall quality of care for patients with structural heart issues.

### Supportive Regulatory Environment

The regulatory environment in the UK is becoming increasingly supportive of innovations in the structural heart-devices market. Regulatory bodies, such as the Medicines and Healthcare products Regulatory Agency (MHRA), are streamlining the approval processes for new devices, which encourages manufacturers to invest in research and development. This supportive framework not only facilitates quicker access to market for new technologies but also enhances patient safety through rigorous evaluation standards. As a result, the structural heart-devices market is likely to benefit from a steady influx of innovative products, which can address the evolving needs of patients and healthcare providers alike. The combination of regulatory support and technological advancements may lead to a more dynamic and competitive market landscape.

### Technological Innovations in Device Design

Technological innovations in the design and functionality of structural heart devices are transforming the market landscape in the UK. Advances in materials science and engineering have led to the development of devices that are not only more effective but also safer for patients. For instance, the introduction of bioresorbable materials and improved delivery systems has enhanced the performance of devices used in minimally invasive procedures. These innovations are likely to attract more healthcare providers to adopt structural heart devices, thereby expanding the market. Furthermore, ongoing research and development efforts are expected to yield even more sophisticated devices in the coming years, which could further stimulate growth in the structural heart-devices market.

### Rising Prevalence of Cardiovascular Diseases

The increasing incidence of cardiovascular diseases in the UK is a primary driver for the structural heart-devices market. According to recent health statistics, cardiovascular diseases account for approximately 27% of all deaths in the UK, highlighting a critical need for effective treatment options. This growing health concern is prompting healthcare providers to seek advanced solutions, including structural heart devices, to manage conditions such as heart valve disorders and congenital heart defects. The demand for innovative devices is expected to rise as the population ages and the prevalence of risk factors, such as obesity and diabetes, increases. Consequently, The structural heart-devices market is likely to experience substantial growth. This growth will occur as healthcare systems adapt to these challenges and invest in new technologies to improve patient outcomes.

## Future Outlook

The [Structural Heart Devices Market](https://www.marketresearchfuture.com/reports/structural-heart-devices-market-6385) is projected to grow at a 6.63% CAGR from 2025 to 2035, driven by technological advancements, increasing prevalence of heart diseases, and rising healthcare expenditure.

**New opportunities:**

- Development of minimally invasive surgical techniques for heart valve repair.
- Expansion of telehealth services for remote patient monitoring.
- Investment in AI-driven analytics for personalized treatment plans.

By 2035, the market is expected to achieve substantial growth, driven by innovation and increasing demand.

## Segment Insights

### By Type: Transcatheter Aortic Valve Replacement (Largest) vs. Mitral Valve Repair Devices (Fastest-Growing)

In the UK structural heart-devices market, the market share distribution highlights that Transcatheter Aortic Valve Replacement (TAVR) leads as the largest segment, holding a significant portion of the total market share. Mitral Valve Repair Devices follow, showcasing robust performance and increasing adoption rates. Left Atrial Appendage Closure Devices and Transcatheter Pulmonary Valve segments have comparatively smaller shares, indicating niche capabilities within the broader market landscape.

Growth trends indicate that Mitral Valve Repair Devices are the fastest-growing segment, driven by advancements in technology and increasing prevalence of mitral valve disorders. The aging population in the UK and rising awareness of minimally invasive procedures are propelling demand for TAVR, while innovations in device designs contribute to the overall growth in the structural heart-devices space. Continued research and development efforts are expected to further enhance these trends moving forward.

Transcatheter Aortic Valve Replacement (Dominant) vs. Mitral Valve Repair Devices (Emerging)

Transcatheter Aortic Valve Replacement (TAVR) is characterized by its dominance in the UK structural heart-devices market, owing to its proven effectiveness and widespread acceptance among healthcare professionals. This segment provides patients with a minimally invasive solution for aortic valve stenosis, making it a preferred choice in clinical practice. Mitral Valve Repair Devices, on the other hand, are emerging rapidly, leveraging innovative technologies that improve patient outcomes and reduce recovery times. The growth of this segment is underpinned by an increase in mitral valve disease diagnoses and the need for effective treatment options. Both segments are vital, yet TAVR remains the stalwart, while Mitral Valve Repair Devices position themselves as a strong contender in the evolving market.

### By Procedure Type: Minimally Invasive (Largest) vs. Surgical (Fastest-Growing)

In the UK structural heart-devices market, the procedure type segment has seen varied distribution with Minimally Invasive practices holding the largest market share. Surgical methods also occupy a significant portion of the market; however, they are increasingly being overshadowed by the growing preference for less invasive options. This shift is driven by patient comfort and recovery time, which are critical factors influencing decision-making in clinical settings.

The growth trends indicate that Minimally Invasive procedures will continue to dominate in the foreseeable future, while Surgical techniques are noted for their rapid advancements and innovations. The drive towards quicker recovery and lower infection rates has spurred interest and investments in this segment. Furthermore, the rise in geriatric population and associated heart conditions fuels the demand for effective surgical solutions, positioning them as a vital part of the overall market dynamics.

Minimally Invasive (Dominant) vs. Surgical (Emerging)

Minimally Invasive methods are characterized by less trauma to the body, which leads to quicker recovery times and reduced hospital stays, making them an attractive option for patients and healthcare providers alike. These techniques are often performed with smaller incisions and involve advanced imaging technologies, enabling precision in procedures. On the other hand, Surgical methods, albeit slower-growing, are being revitalized through technological innovations such as robotic-assisted surgeries and enhanced surgical techniques. While they traditionally require larger incisions and longer recovery periods, advancements are closing the gap between these two segments, making Surgical approaches more competitive in today's rapidly evolving healthcare landscape.

### By Indication: Aortic Stenosis (Largest) vs. Mitral Regurgitation (Fastest-Growing)

The market share distribution for the 'Indication' segment reveals Aortic Stenosis as the largest segment, holding a significant portion of the overall market. In contrast, Mitral Regurgitation is recognized as the fastest-growing segment, showcasing an increasing preference for treatment options. Heart Failure and Pulmonary Valve Stenosis also contribute to the market, but to a lesser extent, highlighting a diverse range of treatment modalities available for clinicians.

Growth trends in the UK structural heart-devices market are significantly influenced by technological advancements and an increasing prevalence of cardiovascular diseases. The rise in patient awareness and improvements in diagnostic methods are driving the demand for devices catering to Aortic Stenosis and Mitral Regurgitation, while ongoing clinical studies are expected to further stimulate market growth for these segments. Investment in healthcare infrastructure is also contributing to the expansion of treatment capabilities.

Aortic Stenosis (Dominant) vs. Mitral Regurgitation (Emerging)

Aortic Stenosis remains the dominant indication in the structural heart-devices market, characterized by a well-established treatment regimen and a wide array of innovative devices tailored for its management. This segment benefits from a robust understanding of its pathophysiology, leading to effective surgical and minimally invasive solutions. On the other hand, Mitral Regurgitation, though emerging, is rapidly gaining traction due to increasing awareness and growing clinical evidence supporting new therapies. The expanding options for Mitral Regurgitation devices are enhancing their appeal in the clinical setting, helping to address a significant unmet need in the market. The differentiation in treatment approaches between these two indications signifies the diverse dynamics influencing the overall market landscape.

### By End User: Hospitals (Largest) vs. Ambulatory Surgical Centers (Fastest-Growing)

In the UK structural heart-devices market, hospitals represent the largest segment, capturing a significant share of the total market. This dominance can be attributed to their established infrastructure, comprehensive cardiac care services, and the presence of specialized healthcare professionals trained in advanced procedural techniques. Ambulatory surgical centers are rapidly capturing attention, offering enhanced patient convenience and efficiency, thus contributing to a notable increase in their market share.

The growth trends indicate a shift towards outpatient procedures, significantly benefiting ambulatory surgical centers, which are seen as an emerging alternative to traditional hospital settings. Factors such as cost-effectiveness, reduced recovery times, and increasing patient preference for minimally invasive interventions are driving this trend. As patient volumes rise and technologies advance, ambulatory surgical centers are positioned as a critical player in the evolving landscape of cardiac care.

Hospitals (Dominant) vs. Ambulatory Surgical Centers (Emerging)

Hospitals are characterized by their comprehensive service offerings, advanced medical technologies, and highly specialized personnel that cater to serious cardiovascular conditions. As the dominant force in the UK structural heart-devices market, they provide a wide range of treatments and interventions for complex heart conditions, ensuring optimal patient outcomes. On the other hand, ambulatory surgical centers represent an emerging segment, focusing on providing swift and efficient procedures with less overhead compared to hospitals. Their increasing popularity stems from the growing trend towards outpatient care, allowing patients to receive high-quality treatment in a less intensive environment. This shift demonstrates a fundamental change in patient care preferences and market dynamics.

## Competitive Benchmarking

The structural heart-devices market is characterized by a dynamic competitive landscape, driven by technological advancements and an increasing prevalence of cardiovascular diseases. Key players such as Edwards Lifesciences (US), Medtronic (US), and Abbott Laboratories (US) are at the forefront, each adopting distinct strategies to enhance their market positioning. Edwards Lifesciences (US) focuses on innovation, particularly in transcatheter heart valves, while Medtronic (US) emphasizes a broad portfolio that includes both surgical and minimally invasive solutions. Abbott Laboratories (US) is leveraging its expertise in imaging and diagnostics to complement its device offerings, thereby creating a comprehensive approach to patient care. Collectively, these strategies foster a competitive environment that prioritizes innovation and patient outcomes.
In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and enhance supply chain efficiency. This trend is particularly evident in the UK, where firms are optimizing their operations to meet local demand while navigating regulatory landscapes. The market structure appears moderately fragmented, with several players vying for market share, yet the influence of major companies remains substantial. Their collective actions shape pricing strategies and product availability, impacting overall market dynamics.
In October 2025, Edwards Lifesciences (US) announced the launch of its next-generation transcatheter aortic valve replacement (TAVR) system, which is designed to improve patient outcomes through enhanced delivery mechanisms. This strategic move underscores the company's commitment to innovation and positions it to capture a larger share of the growing TAVR market. The introduction of this advanced system is likely to strengthen Edwards' competitive edge, particularly as the demand for minimally invasive procedures continues to rise.
In September 2025, Medtronic (US) expanded its partnership with a leading UK healthcare provider to enhance access to its structural heart devices. This collaboration aims to streamline the distribution of Medtronic's products, ensuring that healthcare professionals have timely access to the latest technologies. Such strategic alliances are crucial in a market where rapid access to innovative solutions can significantly influence patient care and outcomes.
In August 2025, Abbott Laboratories (US) unveiled a new digital platform designed to integrate its structural heart devices with advanced analytics and AI capabilities. This initiative not only enhances the functionality of its devices but also positions Abbott as a leader in the digital transformation of healthcare. By leveraging data analytics, Abbott aims to provide personalized treatment options, thereby improving patient engagement and satisfaction.
As of November 2025, the competitive trends in the structural heart-devices market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in enhancing their product offerings and market reach. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift suggests that companies that prioritize these elements will be better positioned to thrive in an increasingly complex market.

## Recent News & Developments

_The UK Structural Heart Devices Market has witnessed significant developments in recent months, particularly with advancements in minimally invasive procedures and the adoption of innovative technologies. Companies like Medtronic and Abbott Laboratories continue to lead in product innovations, focusing on devices such as transcatheter aortic valves and left atrial appendage closure devices. In April 2023, Boston Scientific announced the successful completion of its acquisition of a portfolio of innovative structural heart offerings from a smaller firm, enhancing its market presence in the UK. Additionally, Edwards Lifesciences has expanded its range of heart valve replacement solutions, bolstering its competitive position. _

_The growing incidence of heart diseases, supported by statistics from the UK NHS indicating a constant rise in cardiovascular conditions among aging populations, has led to surges in demand for structural heart devices. These developments contribute to a market projected to grow significantly, with analysts citing that the UK market's value will increase notably by 2025. Recent efforts by Terumo Corporation and MicroPort Scientific to collaborate with healthcare providers for streamlining__treatment protocols reflect a shift towards improved patient outcomes in structural heart conditions, further underlining the dynamic nature of this sector._

## Report Scope

| MARKET SIZE 2024 | 28.88(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 30.79(USD Million) |
| MARKET SIZE 2035 | 58.5(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.63% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Edwards Lifesciences (US), Medtronic (US), Abbott Laboratories (US), Boston Scientific (US), LivaNova (GB), Terumo Corporation (JP), Cardinal Health (US), AtriCure (US) |
| Segments Covered | Type, Procedure Type, Indication, End User |
| Key Market Opportunities | Advancements in minimally invasive procedures enhance growth potential in the structural heart-devices market. |
| Key Market Dynamics | Technological advancements and regulatory changes drive innovation in the structural heart-devices market. |
| Countries Covered | UK |

## Frequently Asked Questions

**Q: What is the current valuation of the UK structural heart-devices market?**
A: The market valuation was $28.88 Million in 2024.

**Q: What is the projected market size for the UK structural heart-devices market by 2035?**
A: The market is projected to reach $58.5 Million by 2035.

**Q: What is the expected CAGR for the UK structural heart-devices market during the forecast period 2025 - 2035?**
A: The expected CAGR is 6.63% during the forecast period.

**Q: Which companies are the key players in the UK structural heart-devices market?**
A: Key players include Edwards Lifesciences, Medtronic, Abbott Laboratories, Boston Scientific, LivaNova, Terumo Corporation, Cardinal Health, and AtriCure.

**Q: What are the main segments of the UK structural heart-devices market?**
A: The main segments include Type, Procedure Type, Indication, and End User.

**Q: What was the valuation of Transcatheter Aortic Valve Replacement in 2024?**
A: The valuation for Transcatheter Aortic Valve Replacement was between $10.0 Million and $20.0 Million.

**Q: How much is the Mitral Valve Repair Devices segment valued at in 2024?**
A: The Mitral Valve Repair Devices segment was valued between $8.0 Million and $15.0 Million in 2024.

**Q: What is the projected valuation for Left Atrial Appendage Closure Devices by 2035?**
A: The projected valuation for Left Atrial Appendage Closure Devices may increase significantly by 2035.

**Q: Which end user segment had the highest valuation in 2024?**
A: The Hospitals segment had the highest valuation, ranging from $10.88 Million to $22.5 Million.

**Q: What is the expected growth trend for the UK structural heart-devices market?**
A: The market appears to be on a growth trajectory, driven by advancements in technology and increasing demand.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/uk-structural-heart-devices-market-56900*